Hyperthermic Intraperitoneal Chemotherapy After Cytoreductive Surgery; Experience and Short Term Outcomes
Abstract
Background: Cytoreductive surgery + hyperthermic intraperitoneal chemotherapy is an important treatment option in patients with a primary diagnosis of colorectal cancer, ovarian cancer, appendix cancer, gastric cancer(selected cases), malignant peritoneal mesothelioma, and peritoneal pseudomyxoma in the presence of peritoneal involvement and resectable lesions limited to the abdomen. In this study, it was aimed to discuss cytoreductive surgery(CRS) with hyperthermic intraperitoneal chemotherapy(HIPEC) in the light of literature.
Methods: The data of patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy between June 2017 and September 2020 at our institution were analyzed. The study was designed retrospectively, and all patients who were discussed at the oncology council and decided on CRS + HIPEC were included in the study.
Results: 31 patients were included in the study. Primary diagnoses of the patients were colorectal cancer in 15 (48%), ovarian cancer in 9 (29%), stomach cancer in 3 (10%), mesothelioma in 2 (7%), appendix cancer in 1 (3%), and also peritoneal pseudomyxoma in 1 (3%). Therapeutic HIPEC was performed in 30 patients, and prophylactic HIPEC was performed in 1 patient. Cytoreduction score was 0 in all patients. The median peritoneal cancer index was 15 (7-29). the median number of resected organs was 3(1-6). Stoma
formation was performed in 14 patients (45%). During the postoperative 30 days, mortality was observed in 1 patient (3%) and morbidity in 5 patients (16%).
Conclusion: The early postoperative mortality and morbidity results reported in our study are compatible with those in the literature.
Keywords
Peritoneal Carcinomatosis , Cytoreductive Surgery , Hyperthermic Intraperitoneal Chemotherapy.
References
- 1. Topgül K, Çetinkaya MB, Arslan NÇ, Gül MK, Çan M, Gürsel MF, et al. Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical details. Ulus Cerrahi Derg. 2015;31(3):138-47.
- 2. Aksel B, Karaman N, Yüksel E, Kahraman YS, Doğan L, Gülçelik MA. Sindirim Sistemi Tümörlerinde Peritonitis Karsinomatoza Ne Kadar Öngörülebilir? Acta Oncol Tur.. 2017; 50(1): 7-11
- 3. Miura JT, Johnston FM, Gamblin TC, Turaga KK. Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol. 2014;21(12):3947-53.
- 4. Minareci Y, Sözen H, Tosun ÖA, Çelik E, Çeliksoy HY, Baktiroğlu M, et al. Practice of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in gynecological cancers: Technical detail and short-term results. Türk Jinekolojik Onkoloji Dergisi.21(2):1-7.
- 5. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29-42.
- 6. Hsieh M-C, Lu C-Y, Chang W-W, Wu S-Y, Hsiao P-K, Liu T-J. Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan. Medicine. 2017;96(26).
- 7. Elias D, Goéré D, Dumont F, Honoré C, Dartigues P, Stoclin A, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer. 2014;50(2):332-40.
- 8. Arjona-Sanchez A, Esquivel J, Glehen O, Passot G, Turaga K, Labow D, et al. A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis. Surg Endosc. 2019;33(3):854-860.
- 9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):64955.
- 10. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-74.